Literature DB >> 10075163

An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines.

D K Xing1, R G Das, L Williams, C Canthaboo, J Tremmil, M J Corbel.   

Abstract

Whole cell and five different types of acellular pertussis vaccine were assayed using a mouse aerosol challenge model which permitted delivery of a controlled, consistent dose of Bordetella pertussis to the lower respiratory tract. Using this system, the viable counts in the lungs of vaccinated mice were immunisation dose-dependent and allowed the protective capacity of different vaccine preparations to be distinguished. This model may thus provide the basis for a protection assay for pertussis vaccines. Comparison of acellular vaccines with a whole cell pertussis vaccine showed that the latter gave better active protection in mice but with a different dose-response relationship. Thus the two types of vaccine are not directly comparable in the same assay and require different reference standards. A pentavalent type acellular vaccine is suggested as a possible candidate standard for the acellular vaccine potency test. The results suggest that this aerosol challenge model has potential for use as a potency test for acellular pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075163     DOI: 10.1016/s0264-410x(98)00235-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Investigation of role of nitric oxide in protection from Bordetella pertussis respiratory challenge.

Authors:  C Canthaboo; D Xing; X Q Wei; M J Corbel
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.

Authors:  N K Fry; S Neal; T G Harrison; E Miller; R Matthews; R C George
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  Characterization of co-purified acellular pertussis vaccines.

Authors:  Yinghua Xu; Yajun Tan; Catpagavalli Asokanathan; Shumin Zhang; Dorothy Xing; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Relationship of immunogenicity to protective potency in acellular pertussis vaccines.

Authors:  Dorothy Xing; Catpagavalli Asokanathan; Ying Hua Xu; Barbara Bolgiano; Alex Douglas-Bardsley; Shumin Zhang; Junzhi Wang; Michael Corbel
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Authors:  Catpagavalli Asokanathan; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

6.  T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice.

Authors:  C M Ausiello; R Lande; P Stefanelli; C Fazio; G Fedele; R Palazzo; F Urbani; P Mastrantonio
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

7.  Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.

Authors:  Caroline Roduit; Paola Bozzotti; Nathalie Mielcarek; Paul-Henri Lambert; Giuseppe del Giudice; Camille Locht; Claire-Anne Siegrist
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model.

Authors:  Seung Beom Han; Kyu Ri Kang; Dong Ho Huh; Hee Chul Lee; Soo Young Lee; Jong-Hyun Kim; Jae Kyun Hur; Jin Han Kang
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

9.  Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

Authors:  Pádraig J Ross; Caroline E Sutton; Sarah Higgins; Aideen C Allen; Kevin Walsh; Alicja Misiak; Ed C Lavelle; Rachel M McLoughlin; Kingston H G Mills
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  Modeling Immune Evasion and Vaccine Limitations by Targeted Nasopharyngeal Bordetella pertussis Inoculation in Mice.

Authors:  Illiassou Hamidou Soumana; Bodo Linz; Kalyan K Dewan; Demba Sarr; Monica C Gestal; Laura K Howard; Amanda D Caulfield; Balázs Rada; Eric T Harvill
Journal:  Emerg Infect Dis       Date:  2021-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.